Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes
- PMID: 35683397
- PMCID: PMC9181473
- DOI: 10.3390/jcm11113008
Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes
Abstract
The treatment of acute coronary syndrome (ACS) in elderly patients continues to be a challenge because of the characteS.G.B.ristics of this population and the lack of data and specific recommendations. This review summarizes the current evidence about critical points of oral antithrombotic therapy in elderly patients. To this end, we discuss the peculiarities and differences reported referring to dual antiplatelet therapy (DAPT) in ACS management in elderly patients and what might be the best option considering these population characteristics. Furthermore, we analyze antithrombotic strategies in patients with atrial fibrillation (AF), with a particular focus on those cases that also present coronary artery disease (CAD). It is imperative to deepen our knowledge regarding the management of these challenging patients through real-world data and specifically designed geriatric studies to help resolve the questions remaining in their disease management.
Keywords: acute coronary syndrome; antiplatelet therapy; clopidogrel; elderly; prasugrel; ticagrelor.
Conflict of interest statement
D.V. reports scientific consulting with AstraZeneca, Bayer, Lilly, Boehringer-Ingelheim, Daichii-Sankyo, and Pfizer-BMS. C.B. reports scientific consulting with AstraZeneca, Bayer, Lilly, Boehringer-Ingelheim, Daichii-Sankyo, and Pfizer-BMS. JLF reports (a) honoraria for lectures from Eli Lilly Co., Daiichi Sankyo, Inc., AstraZeneca, Roche Diagnostics, Pfizer, Abbott, Ferrer, Boehringer Ingelheim, Bristol-Myers Squibb, and Rovi; (b) consulting fees from AstraZeneca, Eli Lilly Co., Ferrer, Boston Scientific, Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Bristol-Myers Squibb; (c) research grants from AstraZeneca. J.N. reports personal fees from AstraZeneca, Novartis, Boehringer-Ingelheim, Eli Lilly Co., Rovi, NovoNordisk, and Vifor Pharma. S.R.R. reports scientific consulting with AstraZeneca, Amgen, Bayer, Boehringer-Ingelheim, Daichii-Sankyo, and Pfizer-BMS.
Similar articles
-
Antithrombotic therapy in coronary artery disease patients with atrial fibrillation.BMC Cardiovasc Disord. 2020 Jul 6;20(1):323. doi: 10.1186/s12872-020-01609-8. BMC Cardiovasc Disord. 2020. PMID: 32631244 Free PMC article.
-
Ticagrelor or prasugrel vs. clopidogrel in combination with anticoagulation for treatment of acute coronary syndrome in patients with atrial fibrillation.Ann Transl Med. 2019 Sep;7(17):406. doi: 10.21037/atm.2019.07.41. Ann Transl Med. 2019. PMID: 31660305 Free PMC article. Review.
-
Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation.Int J Cardiol. 2020 Nov 1;318:82-85. doi: 10.1016/j.ijcard.2020.05.024. Epub 2020 May 8. Int J Cardiol. 2020. PMID: 32389765
-
Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review.JAMA. 2021 Apr 20;325(15):1545-1555. doi: 10.1001/jama.2021.0716. JAMA. 2021. PMID: 33877270 Review.
-
Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update.Front Cardiovasc Med. 2021 Jun 28;8:660986. doi: 10.3389/fcvm.2021.660986. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34262952 Free PMC article.
Cited by
-
Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study.J Clin Med. 2022 Dec 14;11(24):7423. doi: 10.3390/jcm11247423. J Clin Med. 2022. PMID: 36556039 Free PMC article.
-
The Benefits of a Comprehensive Cardiac Rehabilitation Program for Patients with Acute Coronary Syndrome: A Follow-Up Study.J Pers Med. 2023 Oct 21;13(10):1516. doi: 10.3390/jpm13101516. J Pers Med. 2023. PMID: 37888127 Free PMC article.
-
Non-ST Elevation Myocardial Infarction in the Elderly. Antithrombotic Therapy and Beyond.Rev Cardiovasc Med. 2023 Jul 13;24(7):201. doi: 10.31083/j.rcm2407201. eCollection 2023 Jul. Rev Cardiovasc Med. 2023. PMID: 39077013 Free PMC article. Review.
-
Invasive Strategy in Octogenarians with Non-ST-Segment Elevation Acute Myocardial Infarction.Rev Cardiovasc Med. 2024 Feb 28;25(3):78. doi: 10.31083/j.rcm2503078. eCollection 2024 Mar. Rev Cardiovasc Med. 2024. PMID: 39076933 Free PMC article. Review.
References
-
- Andreotti F., Rocca B., Husted S., Ajjan R.A., Berg J.T., Cattaneo M., Collet J.P., De Caterina R., Fox K.A., Halvorsen S., et al. Antithrombotic therapy in the elderly: Expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur. Heart J. 2015;36:3238–3249. doi: 10.1093/eurheartj/ehv304. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous